ArticleFrontiers in nutrition2025
Neutrophil-to-albumin ratio predicts long-term prognosis in coronary heart disease: a prospective cohort study of 2,990 patients.
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cardiovascular diseases (CVDs), particularly coronary heart disease (CHD), impose a global health burden with unpredictable major adverse cardiovascular events (MACE) despite optimal treatment. Systemic inflammation and malnutrition are key pathogenic drivers, yet integrated biomarkers capturing this duality are lacking. The Neutrophil-to-Albumin Ratio (NPAR) emerges as a cost-effective indicator reflecting both pathways, but its prognostic value for post-discharge MACE in hospitalized CHD patients remains unestablished. Our study aimed at investigating the prognostic value of NPAR for MACE in CHD patients. Methods: This prospective cohort study enrolled CHD patients (2013-2020) from the First Affiliated Hospital of Xi'an Jiaotong University. NPAR was calculated from admission blood samples. Participants were stratified into NPAR tertiles (T1: 5.21-16.00; T2: 16.01-18.50; T3: 18.51-42.38). Multivariable Cox models (adjusting for demographics, comorbidities, and laboratory parameters) assessed NPAR-MACE associations. Restricted cubic splines (RCS) and subgroup analyses explored nonlinearity and effect modifiers. Results: A total of 2,990 patients with CHD were eligible for analysis. With a median follow-up of 70 months, Kaplan-Meier survival curves demonstrated that participants in the highest NPAR tertile (T3) exhibited significantly lower cumulative survival rates free from MACE compared to those in the lowest tertile (T1). The highest NPAR tertile (T3) exhibited a 72% increased MACE risk (adjusted hazard ratio (HR) = 1.72, 95% confidence interval (CI): 1.36-2.20) versus T1. A J-shaped relationship emerged, with risk escalating above NPAR = 17 (P nonlinear = 0.01). Sex-specific heterogeneity was observed: males in T3 had markedly elevated risk (HR = 2.03, 95% CI: 1.50-2.75; P interaction = 0.03). Conclusion: Elevated admission NPAR independently predicts long-term MACE in CHD patients, particularly among males. This supports NPAR's utility for post-discharge risk stratification.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.